GSK’s partner Hansoh Pharma succeeds in Chinese Phase III SCLC ADC trial

GSK signed an exclusive licence deal for the ADC with Hansoh Pharma in 2023, laying out up to $1.71bn in an upfront payment plus milestones. GSK signed an exclusive licence deal with Hansoh Pharma in 2023, laying out up to $1.71bn in an upfront payment plus milestones. GSK is evaluating the ADC in a Phase III trial in the US. Credit: Magda Wygralak / Shutterstock.com GSK’s bet on Hansoh Pharmaceutical’s antibody-drug conjugate (ADC) seems to be paying off as the drug met all its endpoints in a Phase III trial in China. In the pivotal ARTEMIS-008 trial (NCT06498479), risvutatug rezetecan…

Source: Clinical Trials Arena